Background: Elevated B-type natriuretic peptide levels in patients with acute myocardial infarction are useful in the prediction of poor outcome. It is still not established how often and when assessment of neurohormonal activation provides the best prognostic information.
identifies patients with a high in-hospital event rate risk. (Int Heart J 2006; 47: 843-854) Key words: Acute coronary syndromes, Acute myocardial infarction, Brain natriuretic peptide, Creatine kinase myocardial band, Percutaneous coronary intervention, ST-elevation myocardial infarction B-TYPE natriuretic peptide (BNP) and the N-terminal fragment of the BNP prohormone (NT-proBNP) are secreted by the myocardium in response to ventricular overload. 1, 2) They are released and rise rapidly in acute myocardial infarction (AMI). [3] [4] [5] Increased BNP and NT-proBNP levels in patients with acute coronary syndromes (ACS) are useful in the prediction of poor outcome. [6] [7] [8] Some studies have documented the relationship between BNP levels measured in the acute phase of AMI and a worse long-term prognosis, 2, [9] [10] [11] while others indicate that later sampling during hospitalization better predicts the outcome.
12) The optimum time of BNP sampling to predict short-term prognosis following AMI in patients treated with primary percutaneous coronary intervention (PCI) has not been previously established.
The aim of this prospective study was to evaluate whether repeated measurements of BNP concentration provide any additional prognostic information concerning in-hospital outcome in patients with first ST-elevation myocardial infarction (STEMI) treated with primary PCI.
METHODS

Patient population:
Between December 2004 and February 2005, 96 patients (68 men, mean age, 63 ± 11.5 years), admitted to our department with symptoms of first STEMI and treated with primary PCI within the first 12 hours from the onset of chest pain, were included in the study. According to the inclusion and exclusion criteria the patients were selected out of the 178 consecutive STEMI patients. The diagnosis of STEMI was made on the basis of typical chest pain, ST-segment elevation of > 0.2 mV in precordial or 0.1 mV in peripheral leads in at least 2 contiguous leads in standard 12-lead electrocardiograms, and typical elevation of creatine kinase myocardial band (CK-MB). Patients with any history of previous MI, severe valvular disease, cardiomyopathy, any form of congenital cardiac disease, or previous symptoms of heart failure (HF) were excluded. All patients on admission were assessed according to TIMI Risk Score 14) and Killip classes. The study design complied with the Helsinki Declaration of 1975 as revised in 1996 and it was approved by the local institutional committee on human research (Institutional Review Board -Local Bioethics Committee of Bia-Vol 47 No 6 lystok Medical University). Informed consent was obtained from all participants. Percutaneous angioplasty procedure and pharmacotherapy: Patients who had had primary PCI performed within the first 12 hours from the onset of chest pain were exclusively included in the study. In the entire study group diagnostic angiography and angioplasty were accomplished by a femoral approach. PCI was successful (TIMI flow grade 3) in most of the patients (92.7%), however, in 4 patients TIMI flow grade after the procedure was 0. Bare metal stents were implanted in 89 of 96 patients. Before PCI all patients received a bolus of weight adjusted unfractionated heparin. Administration of glycoprotein IIb/IIIa inhibitors was left to the discretion of the attending physician.
All patients received aspirin at a dose of 300 mg (followed by 150 mg daily) and ticlopidine (500 mg) or clopidogrel (300 mg) if stents were implanted. Antiplatelet treatment with ticlopidine (250 mg twice daily) or clopidogrel (75 mg daily) was continued for at least one month after the procedure. All patients received statins; other medications, including nitrates, beta-blockers, angiotensin-converting enzyme inhibitors (ACE-I), and calcium channel blockers (CCBs) were administered at the discretion of the physician. Blood sampling and BNP measurements: Peripheral venous blood samples for BNP estimation were obtained on admission and 24 hours later by direct venipuncture after the patient had been resting in the supine position. Blood samples (10 mL) were collected into tubes containing potassium EDTA, centrifuged within 2 hours after sampling, and stored at -70°C until used. Plasma BNP levels were measured using a Microparticle Enzyme Immunoassay kit (MEIA, Abbott, AxSYM, Chicago, Illinois, USA) according to the manufacturer's protocol, not later than 3 months after collection. The AxSYM BNP assay demonstrated an analytical sensitivity of ≤ 15 pg/mL in a study where the AxSYM BNP Standard Calibrator A (0 pg/mL) was assayed multiple times (n = 12 runs in replicates of 10). The clinical sensitivity and specificity of the AxSYM BNP assays for the diagnosis of HF using a decision threshold of 100 pg/mL were 71.0% and 94.8% for males and 80.5% and 88.4% for females, respectively. According to the manufacturer of the assay kits, the intra-assay coefficient of variation (CV %) for BNP is 6.3% at a BNP mean concentration of 95 pg/mL, SD = 6.0.
During the first 24 hours, CK-MB levels were measured every 8 hours. Kinetic determination of creatine kinase isoenzyme CKMB activity by immunoinhibition in human serum was performed using Enzyline CKMB kits (BioMerieux, Lyon, France). The detection limit is less than or equal to 6 U/L. The intra-assay CV % is reported by the manufacturer of the assay kits to be 7.47% at a CKMB mean activity of 33 U/L. Echocardiographic examination: Echocardiograms were performed within the first 24 hours of hospital stay. Complete 2-dimensional echocardiograms includ-ing parasternal long-and short-axis, as well as apical 4-and 2-chamber views were recorded. For the purpose of this study, wall motion index (WMI) and ejection fraction (EF), according to the biplane Simpson method, were analyzed. WMI was calculated using a 16-segment model. Systolic motion of individual segments was assessed as normokinetic (1), hypokinetic (2), akinetic (3), and dyskinetic (4). Composite endpoint: The composite endpoint (CEP) of the study was the occurrence of any major cardiovascular adverse event after the second blood sampling during in-hospital stay, which included: death, reinfarction, ventricular arrhythmias (secondary ventricular fibrillation and/or tachycardia [VF/VT]), new onset of atrial fibrillation (AF), combined atrio-ventricular blocks, stroke and symptoms of advanced HF. Symptoms of HF were assessed according to the NYHA classification daily until discharge or death and advanced CHF was defined as NYHA class III or IV. Statistical analysis: Distribution of the noncategorical variables was assessed using the Shapiro-Wilk test. The Student t test or Mann-Whitney test was used for statistical analysis depending on the distribution. The Spearman correlation was used to present relations between 2 noncategorical variables. Actual numbers of patients were used to present categorical variables, with relative frequencies being given in brackets. These variables were assessed using the chi-square test. A P value of less then 0.05 was considered to be statistically significant. 
RESULTS
The baseline characteristics, risk factors, and clinical findings at presentation of the patients are shown in Table I . Overall, 96 patients were studied with first STEMI. The median TIMI Risk Score was 4.5 (25 th to 75 th percentile: 3.0 to 7.0). Fifty-two patients (54.2%) were in 2 nd or 3 rd Killip classes on admission. None of the patients developed cardiogenic shock. Admission BNP concentrations correlated better with age than the second BNP measurements (Table III) . The biochemical, echocardiographic, and angiographic data are shown in Table  II Although in most of the patients BNP levels were raised after 24 hours, in 16 patients (16.6%) the concentrations were lower after the procedure. Follow-up (hospital stay) lasted 6 ± 4 days. During that time 3 patients died (3.1%). Thirtyfive (36.4%) patients reached the composite endpoint. Symptoms of HF were the most frequent clinical complication, reported in 20 (20.8%) patients. Episodes of atrio-ventricular block occurred in 10 (10.4%) patients, while new onset of AF was observed in 15 (15.6%) patients. Two patients (2.1%) had a stroke.
BNP in correlations with parameters of the infarct size and left ventricular (LV)
function: Both longer pain duration and longer pain-to-balloon time were positively correlated with admission BNP (r = 0.23, P = 0.02 and r = 0.21, P = 0.03, respectively) ( Table III) . The levels of BNP and CKMB obtained on admission were closely correlated (r = 0.31, P = 0.001), while BNP measured 24 hours later was correlated with maximal CKMB levels (r = 0.27, P = 0.006). Although the echocardiographic variables of left ventricular (LV) function were correlated with both BNP measurements, a better correlation was found for the second BNP measurement (WMI: r = 0.41, P = 0.00005 and EF: r = -0.41, P = 0.00004) (Table  III) . The TIMI Risk Score for STEMI was positively correlated with BNP, particularly admission BNP (r = 0.42, P = 0.00002), but also with the second BNP concentration (r = 0.32, P = 0.001) ( Table III) .
In the Mann-Whitney test, median BNP concentration 24 hours after admission was significantly higher in patients who had CEP during hospitalization (P = 0.02, Figure 1 ). This was not observed for BNP measured on admission. Moreover, ROC analysis of BNP concentrations with regard to the estimated CEP, identified only BNP after 24 hours from admission as statistically significant (c = 0.64 CI 0.527 -0.756 P = 0.007) (Figure 2 ). In the study group, the analysis revealed a poor value of admission BNP for prediction of in-hospital cardiovascular events (c = 0.547 CI 0.421 -0.673 P = 0.2335).
DISCUSSION
Previous studies have confirmed that neurohormonal responses, in particular raised levels of BNP and/or NT-proBNP, are independently associated with LV dysfunction and a worse prognosis following AMI. 10, 11) The plasma concentrations of both neurohormones correlate with each other; both have been extensively studied in the setting of acute coronary syndromes. [6] [7] [8] Less is known about how often and when a natriuretic peptide measurement should be performed in order to obtain the most powerful diagnostic and prognostic significance. That is why recent interest has focused on investigating the optimal time of sampling for both BNP and NT-proBNP following acute myocardial infarction. 4, 12, 13) This study was designed to assess if repeated measurement of plasma BNP provides additional information concerning in-hospital outcome in patients with first STEMI treated with primary PCI.
We aimed to investigate the maintenance of BNP concentrations in STEMI patients without previous myocardial injury. Therefore, to avoid the confounding effect of elevated admission BNP levels not related to ongoing AMI, patients with first AMI were selected without any previous history of MI or HF. Thus, we studied lower risk STEMI patients. This could be the explanation why, in contrast to some previous studies, lower mean admission BNP concentrations 8, 16) were found. Moreover, in such a selected study population, in-hospital mortality and the rate of serious adverse events were low. It was demonstrated that despite there being only a 24 hour time interval between the two sets of BNP sampling, they are both of value. Admission BNP collected shortly after the onset of symptoms was mostly related to the age of the patient, pain duration, and admission Killip class. These relations might explain why the correlation with the TIMI Risk Score for STEMI was better for admission BNP than for the second BNP measurement, as it was developed for risk stratification at the time of presentation. 14) In the study group, the second measurement, 24 hours after admission, appeared to be the most powerful predictor of prognosis including death, reinfarction, arrhythmias (AF, VF/VT), atrio-ventricular block, stroke, and symptoms of heart failure. Both measurements correlated with variables, which refer to the infarct size and acute LV dysfunction. It was found that the first BNP measurement, obtained at a median time of about 4 hours from the symptom onset, correlated with admission CKMB, while BNP after 24 hours correlated better with maximal values of CKMB. This suggests that maximal CKMB levels peaking within the first 24 hours of AMI appeared closer to the second BNP measurement, which, according to previous studies, also reaches its first peak within the first 24 hours of infarction. 4, 13) Thus, the results also suggest that 24 hour BNP provides information according to the overload of infarcted ventricles, which correlates to myocardial damage expressed by max. CKMB.
The value of early measurement of natriuretic peptides in ACS patients has been assessed in several studies. However, in most of the studies, BNP was measured only once and the composite endpoint was different. James, et al showed that NT-proBNP measured in ACS patients at a median of 9.5 hours from symptom onset was the strongest (amongst other markers) predictor of mortality.
9) NTproBNP measured even earlier, at a median time of 3 hours after the qualifying anginal episode, was independently associated with death.
15) Also, Grabowski, et al reported that BNP levels obtained on admission in patients with STEMI treated with primary PCI were an independent predictor of short-term follow-up. 16) In addition, they also showed that BNP corresponded well with angiographic success after PCI, but the second measurement after angioplasty was not obtained. The findings of this study are not consistent with these previous studies. In the present study, only BNP obtained 24 hours from admission was associated with an increased risk of in-hospital cardiac events. The present findings support the concept that BNP measured later in the course of AMI is a better predictor of prognosis. Omland, et al found that, on the 3 rd day, sub-acute BNP prohormone release can predict long-term mortality in ACS patients. 7) However, Galvani, et al in meta-analysis of 5 studies concerning the prognostic values of natriuretic peptides, showed that there was no difference when blood was obtained at the time of first patient contact or in the following hours or days after admission. 8) So far, only a few studies have assessed serial BNP measurements in ACS patients. 12, 17) Talwar, et al demonstrated that measurements taken later during hospitalization had a greater value in prediction of poor LV function and a worse prognosis, than when it was estimated in the immediate postinfarction period. 12) It is our belief that this study is the first to indicate that both BNP measurements confirm the acute stage of LV dysfunction in patients with first AMI, while higher levels of BNP 24 hours later enable better selection of patients with a high in-hospital event rate risk. The cumulative endpoint was considered because mortality in the study group was relatively low (3.1%). Previous studies have included patients with a high probability of prior LV dysfunction, which may influence baseline BNP levels. 9, 16) We also believe that there is only one paper evaluating BNP in patients with first AMI. 17) There are several possible reasons why BNP measured later from the onset of AMI predicts a better outcome than the baseline sample. During the acute phase of AMI plasma, BNP levels initially rise within 24 hours and then gradually decrease (monophasic pattern) or show a secondary increase again at 5 to 7 days (biphasic pattern). 4, 13) Early release of BNP is probably caused by ischemiainduced ventricular wall stress.
18) The results of a few studies have proposed a theory that ischemia per se induces production and release of natriuretic peptides. 19) The second, late release of BNP, is considered to be caused by LV remodeling after AMI. 4, 13) In a study by Inoue, et al, the highest levels of BNP were reached 24 hours after onset of AMI, which was the most powerful predictor of chronic stage LV dysfunction. 17) Their findings were in agreement with ours: the second BNP level, obtained 24 hours after admission, correlates better than BNP at baseline with echocardiographic parameters of LV systolic function. On the other hand, it is reasonable to assess BNP in asymptomatic patients with a previous history of myocardial infarction and a low ejection fraction. 20) The data obtained in the present study confirm that plasma levels of BNP are elevated in the early stages of AMI, peaking after 24 hours from the onset of symptoms. A worsened prognosis related to the second BNP measurement for the short-term may have important practical implications. It justifies efforts directed to target specific therapeutic approaches in this high-risk group of patients. Study limitations: The main limitation of this study is the relatively small number of patients studied in relation to the very strict inclusion criteria. Moreover, the selected study group (first STEMI and no history of previous LV dysfunction) was at a relatively low risk of death and in-hospital events. This is why such an extensive composite endpoint was introduced. Acute ischemic stroke was also included in the CEP in a recent publication suggesting the clinical importance of NT-proBNP plasma levels in this group of patients. 21) The patients were included prospectively and were investigated thoroughly, therefore, we believe the results obtained are representative. Other authors have published studies with a similar 16) Vol 47 No 6 or smaller number of patients. 22) Although our study can be considered to be a pilot study, it could be strengthened by a longer term follow-up, which is currently ongoing.
